It's a long way from home.
For those in AI technology entering the healthcare industry, entry is a difficult process.
As Jianpei Technology, which entered the medical AI field in 2012, the company has traveled through the AI industry from cold to hot. The entrepreneurial opportunity stems from Cheng Guohua in other projects, found that most of the hospital's server, more than 80% of the space is image data, Cheng Guohua first birthed the idea of using the Internet way to do medical big data analysis. "2012, 2013, 2014 three years is very lonely, almost always hit the wall, eat all the closed door, we go to the hospital are persuaded by them," Cheng Guohua recalled, a hospital director friend of mine told me at the time, computer-aided diagnostics old long ago, said that this (medical data analytics) has no future.
Until 2015, Jianpei Technology jointly with Huawei and IBM held an international summit forum on medical artificial intelligence, which pushed medical AI into the vision of people in the health care industry, and the emergence of AlphaGo in 2016 has made the concept of artificial intelligence a big fire, and of course, medical AI has also been favored by the capital.
Tumar Deep Dimension (12Sigma) announced in December 2017 the completion of RMB 200 million in Series B financing, becoming the largest financing in the field of medical imaging AI in 2017, which was led by SoftBank China, with participation from C&T Capital and Delian Capital, and continued to be followed up by previous investors Zhenge Fund and Matrix Partners China.
Zhong Xin, CEO of TUMA DeepVision, believes that because of the capital boost, the company's development has far exceeded the expected speed, but the industrialization of medical AI landing, commercialization process is still in the groping stage.